The World Health Organization’s recent endorsement of GLP-1 medications such as Ozempic is prompting renewed discussion about their potential role in treating polycystic ovary syndrome, a hormonal condition affecting millions. Canadian experts say the drugs may help address the metabolic dysfunction linked to PCOS, though more research is needed before they become standard care. Kendra Gannon reports.
Health
WHO endorsement sparks new discussion around GLP-1 drugs and PCOS
More Videos
-
Liberal leader on women’s health and the government deficit
-
Kids Help Phone on navigating complex holiday emotions
-
IWK launches ‘One Person, One Record’ as Nova Scotia begins shift to unified healthcare system
-
Second annual Trees of Joy Halifax event
-
Donation to IWK expected to change scope of women’s health in Maritimes
You are viewing an Accelerated Mobile Webpage.
View Original Article